Valneva SE

Paris Stock Exchange VLA.PA

Valneva SE Return on Capital Employed (ROCE) for the year ending December 31, 2023: -25.00%

Valneva SE Return on Capital Employed (ROCE) is -25.00% for the year ending December 31, 2023, a 28.59% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Valneva SE Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -35.01%, a -156.75% change year over year.
Valneva SE Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -13.64%, a 33.34% change year over year.
Valneva SE Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -20.46%, a -3,973.63% change year over year.
Valneva SE Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 0.53%, a -83.59% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

Paris Stock Exchange: VLA.PA

Valneva SE

CEO	Mr. Thomas Lingelbach
IPO Date	June 29, 2007
Location	France
Headquarters	6 rue Alain Bombard
Employees	676
Sector	Healthcare
Industries Vaccines

Description

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

Key trends

Past 5 years